Public procurement notice: Voluntary Ex Ante Transparency Notice
Published: 2019-02-01
Buyer: Sykehusinnkjøp HF
Country: NO
Contract type: Supplies
Procedure: Contract award without prior publication
CPV classification: 33600000: Pharmaceutical products
Estimated value: 11106000 NOK
Award criteria: Lowest price

Technical requirements: Additional contracts with Specific Pharma A/S after the tender competition LIS 1901 for pharmaceutical special preparations for J01CA01 Ampicillin.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for special pharmaceutical preparations (“LIS 1901 Special Pharmaceutical Preparations”, LIS 1901). The contest was for the active ingredients that were in accordance with the tender documentation, Annex 3 Active Ingredients List.
After the contracts were signed we received tenders for Ampicillin 2 g (ATC-code J01CA01), which there were no tenderers for in the tender competition.
Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Specific Pharma A/S (the Supplier) as an additional contract to LIS 1901, i.e. the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for this ingredient. The Health Trusts included in the Regional Health Authorities, and private, non-profit institutions with an operation agreement with regional hospitals, have an option to enter into the contracts.
LIS has examined the market situation and is of the opinion that it is not possible to have a new competition, or that another supplier than Specific Pharma A/S can deliver the product in this contract period. In addition, the situation that has occurred is not the Contracting Authority's fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. See the Public Procurement Regulations, § 21-5, jf. § 21-2, cf. §§ 13-4 Letter a) and 13-3.
LIS requests that those who have objections to this submit feedback before the waiting period, which is set to 10 days calculated from the day after the publication of the Voluntary ex ante transparency notice. If no objections are received, a contract will be signed after the waiting period has expired.
An additional contract for LIS 1901, i.e. the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for this ingredient.
Sykehusinnkjøp HF, Divisjon legemidler (LIS) is collecting tenders for medicines that are used by the Health Trusts. LIS has previously announced and held an open tender contest for special pharmaceutical preparations (“LIS 1901 Special Pharmaceutical Preparations”, LIS 1901). The contest was for the active ingredients that were in accordance with the tender documentation, Annex 3 Active Ingredients List.
After the contracts were signed we received tenders for Ampicillin 2 g (ATC-code J01CA01), which there were no tenderers for in the tender competition.
Due to this, LIS intends to enter into contracts between the regional health trusts (the Contracting Authorities) and Specific Pharma A/S (the Supplier) as an additional contract to LIS 1901, i.e. the scope and length of the contract will follow the mentioned procurement (including access to extensions and terminations), without a new competition being held for this ingredient. The Health Trusts included in the Regional Health Authorities, and private, non-profit institutions with an operation agreement with regional hospitals, have an option to enter into the contracts.
LIS has examined the market situation and is of the opinion that it is not possible to have a new competition, or that another supplier than Specific Pharma A/S can deliver the product in this contract period. In addition, the situation that has occurred is not the Contracting Authority's fault, nor something that the Contracting Authority could foresee. LIS therefore believes that there are grounds to make the procurement without a competition. See the Public Procurement Regulations, § 21-5, jf. § 21-2, cf. §§ 13-4 Letter a) and 13-3.
LIS requests that those who have objections to this submit feedback before the waiting period, which is set to 10 days calculated from the day after the publication of the Voluntary ex ante transparency notice. If no objections are received, a contract will be signed after the waiting period has expired.


Winner: Specific Pharma AS
Award value: 11106000